{"id":"azilsartan-medoxomil-and-chlorthalidone","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL2028661","moleculeType":"Small molecule","molecularWeight":"568.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone secretion. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing blood volume and peripheral vascular resistance. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:17.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Essential Hypertension","enrollment":507},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Safety","enrollment":153},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Hypertension","enrollment":1711},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00696384","phase":"PHASE3","title":"A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":418},{"nctId":"NCT00591773","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-09","conditions":"Hypertension","enrollment":551},{"nctId":"NCT00695955","phase":"PHASE3","title":"One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":669}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CONSTIPATION"}],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-491","TAK-491CLD","azilsartan medoxomil","chlorthalidone","Edarbi"],"phase":"phase_3","status":"active","brandName":"Azilsartan medoxomil and chlorthalidone","genericName":"Azilsartan medoxomil and chlorthalidone","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}